ClinicalTrials.gg
CompletedNCT05918107Updated Jun 8, 2026

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

A Phase 2 interventional study of PM8002 and Pemetrexed in MPM, sponsored by Biotheus Inc.. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2022, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.

Read the detailed description

PD-L1 and VEGF play important roles in immune escape and tumor angiogenesis and enhance cancer growth and metastasis. PM8002 is a bispecific antibody targeting PD-L1 and VEGF-A. Here, the investigators present the results from a Phase II study of PM8002 in combination with pemetrexed and platinum subjects in unresectable malignant mesothelioma.

02

Conditions studied

  • MPM

Keywords

  • First line
03

In context

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in clinical research; fully understand the study and voluntarily sign the ; willing to follow and have the ability to complete all trial procedures;
  2. Male or female, aged ≥18 years;
  3. Malignant mesothelioma confirmed by histology, without indication for surgery;
  4. Have not received systemic anti-tumor therapy in the past (if the subject has received or adjuvant chemotherapy in the past, the last treatment time must be more than 6 months from the time of recurrence);
  5. Sufficient organ function;
  6. (ECOG) physical status (PS) score is 0-1;
  7. Expected survival period ≥ 12 weeks;
  8. There is at least one (malignant pleural mesothelioma is based on version 1.1, and malignant mesothelioma in other parts is based on version 1.1).

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic diseases, severe drug (including unmarked test drug) allergy history, or known allergy to any component of the drug in this study;
  2. Brain parenchymal or meningeal metastases with clinical symptoms, judged by the investigators as not suitable for inclusion;
  3. Had other active malignant tumors within 5 years before starting the study drug treatment, except for malignant tumors that can be treated locally and cured (such as skin basal cell or squamous cell carcinoma, superficial or non-invasive bladder cancer), cervical carcinoma in situ, breast ductal carcinoma in situ, papillary thyroid carcinoma);
  4. Currently there are uncontrollable pleural, pericardial, and peritoneal effusions, and those with catheter drainage also need to be excluded;
  5. Unexplained fever > 38.5°C before starting the study treatment (judged by the investigator, fever caused by tumor can be included in the group);
  6. There is uncontrollable tumor-related pain, and those who need analgesic treatment should have a stable analgesic treatment plan at the time of screening; asymptomatic metastatic lesions, if they grow further, may cause dysfunction or intractable pain (such as current and spinal cord compression unrelated epidural metastases), local therapy should be considered before screening if appropriate;
  7. Currently have clear interstitial lung disease or non-infectious pneumonia, except radiation pneumonitis caused by local radiotherapy;
  8. There are active infections;
  9. Have a history of immunodeficiency, including a positive test for (HIV) antibodies;
  10. Positive for syphilis antibody;
  11. Expect to receive any other forms of anti-tumor drug treatment during the trial period;
  12. Those who have received hematopoietic stem cell transplantation or organ transplantation in the past;
  13. Pregnant or lactating women;
  14. According to the investigator's judgment, the subject's basic condition may increase the risk of receiving the study drug treatment, or cause confusion for the explanation of the toxic reaction and AE;
  15. Other investigators think that they are not suitable to participate in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Other
    PM8002+pemetrexed+platinum

    Subjects will be administered with PM8002 plus pemetrexed+platinum via intravenously (IV) Q3W for 4-6 cycles,followed by PM8002 until disease progression intolerable toxicity for a maximum of 2 years.

    Drug: PM8002 · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: : Up to approximately 2 years

  2. Treatment related adverse events (TRAEs)

    The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0.

    Time frame: Up to 30 days after last treatment]

Secondary outcomes

  1. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  2. Duration of response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  3. Progression free survival (PFS)

    PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  4. Overall survival (OS)

    OS is the time from the date of first dosing date to death due to any cause.

    Time frame: Up to approximately 2 years

07

Study locations

16 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
  • Chinese PLA General Hospital
    Beijing, China
  • Peking Cancer Hospital
    Beijing, China
  • Jilin Provincial Tumor Hospital
    Changchun, China
  • Chongqing University Cancer Hospital
    Chongqing, China
  • Liaoning Cancer Hospital and Institute
    Dalian, China
  • Fujian Cancer Hospital
    Fuzhou, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
  • Zhejiang Cancer Hospital
    Hangzhou, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • Harbin Medical University Cancer Hospital
    Harbin, China
  • Shandong Cancer Hospital
    Jinan, China
  • Jiangsu Province Hospital
    Nanjing, China
  • Shanghai Pulmonary Hospital
    Shanghai, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, China
  • Henan Cancer Hospital
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract,articles or papers) or any presentations.

Time frame: After the trial completed

Access criteria: NCI is committed to sharing data in accordance with NIH policy

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Mar 2026, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jun 26, 2023
StartActual
Aug 13, 2022
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05918107
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Aug 13, 2022
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Jun 8, 2026

Study contacts

Haifeng Liu
principal investigator · Jilin Provice Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion